Zoning of Mucosal Phenotype, Dysplasia, and Telomerase Activity Measured by Telomerase Repeat Assay Protocol in Barrett's Esophagus

Neoplasia

Volumn 6, Issue 1, 2004, Pages 85-92

  Going, James J ^a,c   Fletcher Monaghan, Aileen J ^a   Neilson, Lisa ^a   Wisman, Bea A ^b   Van Der Zee, Ate ^b   Stuart, Robert C ^a   Keith, W Nicol ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b University Hospital Groeningen   (Netherlands)

^c WESTERN INFIRMARY   (United Kingdom)

Author keywords

Barrett's esophagus; Cancer progression; Dysplasia; Neoplasia; Telomerase

Indexed keywords

BIOLOGICAL MARKER; RNA; RNA DIRECTED DNA POLYMERASE; TELOMERASE;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; BILE REFLUX; CANCER GROWTH; CLINICAL ARTICLE; COLUMNAR EPITHELIUM; DYSPLASIA; ENZYME ACTIVITY; ESOPHAGUS BIOPSY; ESOPHAGUS MUCOSA; FEMALE; GASTROESOPHAGEAL REFLUX; GENE OVEREXPRESSION; GLANDULAR DYSPLASIA; HUMAN; HUMAN TISSUE; INTESTINAL TYPE BARRETT MUCOSA; INTESTINE METAPLASIA; LOWER ESOPHAGUS SPHINCTER; MALE; MUCOSAL PHENOTYPE; NEOPLASM; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS EPITHELIUM; STOMACH ANTRUM; STOMACH BIOPSY; STOMACH MUCOSA; TELOMERIC REPEAT AMPLIFICATION PROTOCOL;

ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; BIOPSY; CELL TRANSFORMATION, NEOPLASTIC; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PHENOTYPE; PRECANCEROUS CONDITIONS; STOMACH; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 1642409823     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Shaheen NJ, Crosby MA, Bozymski EM, and Sandler RS (2000). Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 119, 333-338.
2. Heath EI, Limburg PJ, Hawk ET, and Forastiere AA (2000). Adenocarcinoma of the esophagus: risk factors and prevention. Oncology (Huntington) 14, 507-514.
3. Reid BJ, Levine DS, Longton G, Blount PL, and Rabinovitch PS (2000). Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 95, 1669-1676.
4. Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, Anderson MA, Petterson TM, and Burgart LJ (2001). Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 1120, 1630-1639.
5. Soni A, Sampliner RE, and Sonnenberg A (2000). Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective? Am J Gastroenterol 95, 2086-2093.
6. Macdonald CE, Wicks AC, and Playford RJ (2000). Final results from 10 year cohort of patients undergoing surveillance for Barrett's esophagus: observational study. BMJ 321, 1252-1255.
7. Riddell RH (1996). Early detection of neoplasia of the esophagus and gastroesophageal junction. Am J Gastroenterol 91, 853-863.
8. Wright TA, Gray MR, Morris AI, Gilmore IT, Ellis A, Smart HL, Myskow J, Nash J, Donnelly RJ, and Kingsnorth AN (1996). Cost effectiveness of detecting Barrett's cancer. Gut 39, 574-579.
9. Incarbone R, Bonavina L, Saino G, Bona D, and Peracchia A (2002). Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus. Surg Endosc 16, 263-266.
10. May A, Gossner L, Pech O, Fritz A, Gunter E, Mayer G, Muller H, Seitz G, Vieth M, Stolte M, and Ell C (2002). Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's esophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 14, 1085-1091.
11. Montgomery E, Bronner MP, Goldblum JR, Greenson JK, Haber MM, Hart J, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Toledano AY, Shyr Y, and Washington K (2001). Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 32, 368-378.
12. Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O'Connell S, Seidel UJ, and Sonnenberg A (2001). Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 120, 1607-1619.
13. Krishnadath KK, Reid BJ, and Wang KK (2001). Biomarkers in Barrett esophagus. Mayo Clin Proc 76, 438-446.
14. Keith WN and Evans RM (2001). Telomerase and cancer: time to move from a promising target to a clinical reality. J Pathol 195, 404-414.
15. Downey MG, Going JJ, Stuart RC, and Keith WN (2001). Expression of telomerase RNA in esophageal and oral cancer. J Oral Pathol Med 30, 577-581.
16. Morales CP, Lee EL, and Shay JW (1998). In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer 83, 652-659.
17. Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park J, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, Bremner PI, Tsai PI, and Danenberg PV (2000). Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 4, 135-142.
18. Bryce LA, Morrison N, Hoare SF, Muir S, and Keith WN (2000). Mapping of the gene for the human telomerase reverse transcriptase, hTERT, to chromosome 5p15.33 by fluorescence in situ hybridization. Neoplasia 2, 197-201.
19. Hoare SF, Bryce LA, Wisman GB, Burns S, Going JJ, van der Zee AG, and Keith WN (2001). Lack of telomerase RNA gene hTERC expression in alternative lengthening of telomeres cells is associated with methylation of the hTERC promoter. Cancer Res 61, 27-32.
20. Soder AI, Hoare SF, Muir S, Going JJ, Parkinson EK, and Keith WN (1997). Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene 14, 1013-1021.
21. Soder AI, Hoare SF, Muire S, Balmain A, Parkinson EK, and Keith WN (1997). Mapping of the gene for the mouse telomerase RNA component, Terc, to chromosome 3 by fluorescente in situ hybridization and mouse chromosome painting. Genomics 41, 293-294.
22. Soder AI, Going JJ, Kaye SB, and Keith WN (1998). Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization. Oncogene 16, 979-983.
23. Zhao JQ, Hoare SF, McFarlane R, Muir S, Parkinson EK, Black DM, and Keith WN (1998). Cloning and characterization of human and mouse telomerase RNA gene promoter sequences. Oncogene 16, 1345-1350.
24. Going JJ, Stuart RC, Downie M, Fletcher-Monaghan AJ, and Keith WN (2002). "Senescence-associated" beta galactosidase activity in mucosae of the upper gastrointestinal tract. J Pathol 196, 394-400.
25. Going JJ, Keith WN, Neilson L, Stoeber K, Stuart RC, and Williams GH (2001). Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous esophageal epithelium and Barrett's mucosa. Gut 50, 373-377.
26. Haggitt RC (1994). Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 25, 982-993.
27. Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey MF, Dixon MF, Fenoglio-Preiser CM, Flejou JF, Geboes K, Hattori T, Hirota T, Itabashi M, Iwafuchi M, Iwashita A, Kim YI, Kirchner T, Klimpfinger M, Koike M, Lauwers GY, Lewin KJ, Oberhuber G, Offner F, Price AB, Rubio CA, Shimizu M, Shimoda T, Sipponen P, Solcia E, Stolte M, Watanabe H, and Yamabe H (2000). The Vienna classification of gastrointestinal epithelial neoplasia. Gut 47, 251-255.
28. Schlemper RJ, Kato Y, and Stolte M (2001). Review of histological classifications of gastrointestinal epithelial neoplasia: differences in diagnosis of early carcinomas between Japanese and Western pathologists. J Gastroenterol 36, 445-456.
29. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, VanBelle G, Lewin K, Weinstein WM, Antonioli DA, Goldman H, MacDonald W, Owen D (1988). Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 19, 166-178.
30. Silcocks PB (1983). Measuring repeatability and validity of histological diagnosis - a brief review with some practical examples. J Clin Pathol 36, 1269-1275.
31. Kim NW and Wu F (1997). Advances in quantification and characterisation of telomerase activity by the telomerase repeat amplification protocol. Nucleic Acids Res 25, 2595-2597.
32. Schroder CP, Wisman GB, deJong S, van der Graaf WT, Ruiters MH, Mulder NH, de Leij LF, van der Zee AG, and de Vries EG (2001). Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer 84, 1348-1353.
33. Nakamura Y, Tahara E, Tahara H, Yasui W, and Ide T (1999). Quantitative reevaluation of telomerase activity in cancerous and noncancerous gastrointestinal tissues. Mol Carcinog 26, 312-320.
34. Schmidt HG, Riddell RH, Walther B, Skinner DB, and Riemann JF (1985). Dysplasia in Barrett's esophagus. J Cancer Res Clin Oncol 110, 145-152.
35. Bachor C, Bachor OA, and Boukamp P (1999). Telomerase is active in normal gastrointestinal mucosa and not up-regulated in precancerous lesions. J Cancer Res Clin Oncol 125, 453-460.
36. McArdle JE, Lewin KJ, Randall G, and Weinstein W (1992). Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus. Hum Pathol 23, 479-482.
37. Iijima K, Henry E, Moriya A, Wirz A, Kelman AW, and McColl KE (2002). Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction. Gastroenterology 122, 1248-1257.
38. Vasa M, Breitschopf K, Zeiher AM, and Dimmeler S (2000). Nitric oxide activates telomerase and delays endothelial cell senescence. Circ Res 87, 540-542.
39. Qualman SJ, Murray RD, McClung HJ, and Lucas J (1990). Intestinal metaplasia is age related in Barrett's esophagus. Arch Pathol Lab Med 114, 1236-1240.
40. Rabinovitch PS, Reid BJ, Haggitt RC, Norwood TH, and Rubin CE (1989). Progression to cancer in Barrett's esophagus is associated with genomic instability. Lab Invest 60, 65-71.
41. Wong DJ, Paulson TG, Prevo LJ, Galipeau PC, Longton G, Blount PL, and Reid BJ (2001). p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 61, 8284-8289.
42. Eads CA, Lord RV, Kurumboor SK, Wickramasinghe K, Skinner ML, Long TI, Peters JH, DeMeester TR, Danenberg KD, Danenberg PV, Laird PW, and Skinner KA (2000). Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 60, 5021-5026.
43. Youssef N, Paradis V, Ferlicot S, and Bedossa P (2001). In situ detection of telomerase enzymatic activity in human hepatocellular carcinogenesis. J Pathol 194, 459-465.